TriSalus Life Sciences Form 4 shows new CFO equity awards

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its chief financial officer in a Form 4 filing. On 11/24/2025, the officer received 65,000 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing beneficial ownership of common stock to 265,000 shares held directly.

The filing also reports an employee stock option grant to buy 130,000 shares of common stock at an exercise price of $5.55 per share, expiring on 11/23/2035. The RSU award vests in four equal annual installments starting 11/24/2025, while one-fourth of the option vests on the one-year anniversary of 11/24/2025 and the remaining shares vest monthly over the following three years, in each case subject to continued employment. Following this option grant, the officer beneficially owns 668,899 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patience David

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		A		65,000(1)	A	$0	265,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.55	11/24/2025		A		130,000		(2)	11/23/2035	Common Stock	130,000	$0	668,899	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date.

2. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TriSalus Life Sciences (TLSI) disclose in this Form 4?

The filing discloses that the chief financial officer received an equity compensation package on 11/24/2025, including a restricted stock unit grant and an employee stock option grant tied to TriSalus Life Sciences common stock.

How many TriSalus Life Sciences (TLSI) RSUs were granted to the officer and how do they vest?

The officer received 65,000 restricted stock units payable solely in common stock. These RSUs vest in four equal annual installments starting on November 24, 2025, subject to the officer’s continued employment through each vesting date.

What are the key terms of the TriSalus Life Sciences (TLSI) stock option grant?

The filing reports an employee stock option to purchase 130,000 shares of common stock at an exercise price of $5.55 per share, with an expiration date of 11/23/2035. One-fourth of the shares vest on the one-year anniversary of November 24, 2025, and the remaining shares vest in equal monthly installments over the following three years, subject to continued employment.

How many TriSalus Life Sciences (TLSI) common shares does the officer own after this transaction?

After the reported RSU grant, the officer beneficially owns 265,000 shares of common stock directly.

How many derivative securities of TriSalus Life Sciences (TLSI) does the officer hold after the option grant?

Following the reported stock option grant, the officer beneficially owns 668,899 derivative securities directly, as disclosed in the filing.

What role does the reporting person hold at TriSalus Life Sciences (TLSI)?

The reporting person is identified as an officer of TriSalus Life Sciences, serving as the company’s Chief Financial Officer.